ACA
NBIX icon

Aptus Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Aptus Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Sell
1,325
-489
-27% -$72.5K ﹤0.01% 1080
2026
Q1 		$239K Buy
1,814
+147
+9% +$19.5K ﹤0.01% 950
2025
Q4 		$236K Buy
+1,667
New +$242K ﹤0.01% 974

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aptus Capital Advisors's NBIX Position: Q2 2026 in Review

Aptus Capital Advisors reduced its Neurocrine Biosciences (NBIX) stake by 27% in Q2 2026, selling an estimated $72.5K and leaving 1,325 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #1080.

Aptus Capital Advisors first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. The position peaked at $239K in Q1 2026. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Aptus Capital Advisors held 1,325 shares of Neurocrine Biosciences worth $223K as of Q2 2026.
  • Aptus Capital Advisors sold 489 Neurocrine Biosciences shares in Q2 2026, an estimated $72.5K.
  • Neurocrine Biosciences made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #1080 holding.
  • Aptus Capital Advisors first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Aptus Capital Advisors's Neurocrine Biosciences position peaked at $239K in Q1 2026.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.